Legacy Pharma Inc. SEZC is committed to advancing treatment in antifungal therapy.
For other information, please contact:
Legacy Pharma Inc. SEZC
George Town, Grand Cayman
Cayman Islands
Toll-free: 1-800-727-7151
You can also view our Privacy & Usage Policy for this website.
INDICATIONS AND USAGE: NAFTIN (naftifine hydrochloride) GEL 2% is an allylamine antifungal indicated for the treatment of athlete’s foot between the toes caused by fungus in patients 12 years of age and older.
WARNING: If there is redness or irritation on the skin with the use of NAFTIN GEL 2%, stop treatment and speak with your doctor.
INFORMATION FOR PATIENTS:
1. NAFTIN GEL 2% is only for use on top of the skin. NAFTIN GEL 2% should not be used in the mouth, eyes, or vagina.
2. If there is irritation or redness with the use of NAFTIN GEL 2%, treatment should be stopped. Contact your doctor if you have irritation or redness on the skin after using NAFTIN GEL 2%.
Cancer Risk: It is not known whether NAFTIN causes cancer or causes a risk of cancer. Long-term studies to evaluate the risk of cancer from NAFTIN GEL 2% have not been done.
Pregnancy: Let your doctor know if you are pregnant or plan to become pregnant. NAFTIN GEL 2% should be used during pregnancy only if the benefit to the mother is greater than the risk to the unborn baby.
Nursing Mothers: It is not known whether this drug passes into breast milk. Because many drugs pass into breast milk, women who are nursing should take care when using NAFTIN GEL 2%.
Pediatric Use: Safety and effectiveness in children under 12 years old has not been proven.
SIDE EFFECTS: In clinical trials with NAFTIN GEL 2%, the most common side effect was itching on the skin where the medicine was applied.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
REFERENCES: 1. Vlahovic TC. Choosing the right vehicle. Podiatr Manage.
June/July 2008;209-214.
2. Data on file, Legacy Pharma Inc. SEZC.
3. Naftin Gel 2%. Package insert. Legacy Pharma Inc. SEZC; 2020.
4. Graybill JR, Burgess DS, Hardin TC. Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis. 1997;16(1):42-50.
5. Plaum S, Verma A, Fleischer AB, Olayinka B, Hardas B. Detection and relevance
of naftifine hydrochloride in the stratum corneum up to four weeks following the last application
of naftifine cream or gel 2%. J Drugs Dermatol. 2013;12(9):1004-1008.
6. Stein Gold L, Parish L, Vlahovic T, Kircik L, et al. Efficacy and safety of
naftifine HCL Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled
results from two multicenter, randomized, double-blind, vehicle-controlled trials.
J Drugs Dermatol. 2013;12(8):911-918.
7. Brennan B, Leyden JJ. Overview of topical therapy for common superficial
fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8.
8. NAFTIN 2% Co-Pay Savings Offer. Legacy Pharma Inc. SEZC, 2023.
9. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind,
vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis.
J Drugs Dermatol. November 2011;10(11):1282-1288.
10. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized,
vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris.
J Drugs Dermatol. October 2011;10(10):1142-1147.
11. Robbins CM, Elston DM. Tinea pedis treatment & management. Updated September 11, 2020. Accessed December 14, 2022. https://emedicine.medscape.com/article/1091684-treatment#showall
12. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and
benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed.
Elsevier Inc. Ebook; 2013:460-472.
13. IQVIA. National Prescription Audit Report. October 2022.